A3P Biomedical AB, a Swedish company specialized in advanced prostate cancer diagnostics, and BioAgilytix, a global bioanalytical services provider, have entered a partnership with the aim of introducing Stockholm3, as a Lab Developed Test (LDT) designed to redefine the standard of care for early detection of prostate cancer in the…
In a recently published article in Läkartidningen (the Swedish Medical Journal), the Prostate Cancer Center at Capio St. Göran’s Hospital is recognized for its structured and cohesive model (the Capio model) which is based on Stockholm3 and provides significantly improved prostate cancer diagnostics and health economics. The Prostate…
Stockholm3 has been mentioned as a biomarker test in the revised 2023 American Urological Association (AUA) guidelines for early detection of prostate cancer. The AUA guidelines cite a publication (Grönberg et al. 2015, Lancet Oncology1) which has shown that Stockholm3 has a higher predictive accuracy compared to PSA alone, with the…
The 38th annual European Association of Urology (EAU) meeting was held March 10-13, 2023 in Milan, Italy. More sophisticated risk adapted strategies was a focus area, including seven abstracts evaluating Stockholm3 performance in populations across Europe. For the third year in a row a Stockholm3 study was awarded and highlighted on the…
Seven scientific abstracts, one thematic session and one plenary session related to Stockholm3 have been accepted for presentation at the upcoming 38th European Association of Urology (EAU) meeting that will be held March-10-13 in Milan, Italy. The accepted presentations, outlined below, cover topics such as validation of Stockholm3 in…
Groves Medical Group has started offering Stockholm3 for prostate cancer testing. This is the first UK clinic that uses Stockholm3.
Stockholm3 will be offered to men aged 45 to 74 in the South-West London area. The blood samples will be taken at the Groves Medical Centre in New Malden, London and the test analysis will be performed by…
A study comparing Stockholm3 with the Rotterdam Prostate Cancer Risk Calculator (RPCRC) has been published in European Urology Focus (1). RPCRC is a prostate cancer risk calculator that is recommended in the European Association of Urology guidelines. Stockholm3 showed superior performance and a positive clinical benefit whereas the…
